UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.55 USD
+0.08 (5.44%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $1.53 -0.02 (-1.29%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
UBX 1.55 +0.08(5.44%)
Will UBX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for UBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for UBX
All You Need to Know About UNITY Biotechnology (UBX) Rating Upgrade to Buy
Unity (UNX) Down on Disappointing Results From Wet AMD Study
UBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now
Other News for UBX
Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment
UNITY Biotechnology, Inc. Reports First Quarter 2024 Financial Results and Business Updates
UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024
Unity Biotechnology GAAP EPS of -$0.34
Unity Biotechnology reports Q1 EPS (34c), consensus (48c)